Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients ; volume:16 ; number:1 ; day:8 ; month:11 ; year:2016 ; pages:1-8 ; date:12.2016
BMC cancer ; 16, Heft 1 (8.11.2016), 1-8, 12.2016
- Urheber
-
Ko, Ryo
- Beteiligte Personen und Organisationen
-
Kenmotsu, Hirotsugu
Serizawa, Masakuni
Koh, Yasuhiro
Wakuda, Kazushige
Ono, Akira
Taira, Tetsuhiko
Naito, Tateaki
Murakami, Haruyasu
Isaka, Mitsuhiro
Endo, Masahiro
Nakajima, Takashi
Ohde, Yasuhisa
Yamamoto, Nobuyuki
Takahashi, Kazuhisa
Takahashi, Toshiaki
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2902-0
- URN
-
urn:nbn:de:1111-201612138616
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ko, Ryo
- Kenmotsu, Hirotsugu
- Serizawa, Masakuni
- Koh, Yasuhiro
- Wakuda, Kazushige
- Ono, Akira
- Taira, Tetsuhiko
- Naito, Tateaki
- Murakami, Haruyasu
- Isaka, Mitsuhiro
- Endo, Masahiro
- Nakajima, Takashi
- Ohde, Yasuhisa
- Yamamoto, Nobuyuki
- Takahashi, Kazuhisa
- Takahashi, Toshiaki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer